Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Gastric Cancer Drugs Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The gastric cancer drugs market has experienced substantial expansion in recent years. This market is projected to expand from $4.9 billion in 2025 to $5.39 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 9.9%. Historically, this growth has been influenced by factors such as the increasing prevalence of gastric cancer, limited awareness regarding early detection, a reliance on conventional chemotherapy, the rising adoption of hospital-based treatment, and the high cost associated with branded drugs.
The gastric cancer drugs market is projected to experience substantial expansion over the upcoming years. This market is set to reach a valuation of $8.14 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.9%. This anticipated growth during the forecast timeframe is primarily driven by improvements in targeted treatments, the rising acceptance of immunotherapy, the broadening scope of precision medicine, the creation of new oral and injectable drug forms, and increased financial backing from both government and private sectors for cancer studies. Key trends anticipated for the forecast period encompass individualized treatments for gastric cancer, the creation of specific drug delivery methods, a greater reliance on combined therapeutic approaches, the extension of outpatient services for cancer treatment, and an increase in supportive care and symptom alleviation efforts.
Get A Free Sample Report With In-Depth Market Insights:
Gastric Cancer Drugs Market Growth Drivers: What’s Behind The Acceleration?
The global gastric cancer drug market is anticipated to expand in the future, largely due to the rising worldwide aging population. This demographic describes a scenario where a substantial portion of a country’s or area’s inhabitants are older, generally aged 65 and above. It arises from a combination of extended life expectancy and declining birth rates, leading to a greater percentage of older individuals within the total populace. Elderly patients often exhibit reduced tolerance for specific cancer therapies like surgery or chemotherapy. Consequently, there is an escalating demand for customized treatment approaches, including pharmaceutical interventions, to cater to the unique requirements and physiological limits of older patients. For example, data from July 2024 provided by the UK Parliament’s House of Commons Library, a UK-based government administration, indicated that in 2022, the UK had 12.7 million individuals aged 65 or older, making up 19% of its total population. This figure is forecast to climb to 22.1 million by 2072, at which point it will constitute 27% of the population. Hence, the gastric cancer drug market is projected to see future expansion, spurred by the increasing senior demographic.
Gastric Cancer Drugs Market Segment Analysis: What Are The Core Market Categories?
The gastric cancer drugs market covered in this report is segmented –
1) By Type: Imatinib, Trastuzumab, Other Types
2) By Route of Administration: Oral, Parenteral
3) By End User: Hospitals, Clinics, Cancer Speciality Centers
Subsegments:
1) By Imatinib: Oral Formulations, Injectable Formulations, Combination Therapies
2) By Trastuzumab: Monotherapy, Combination Therapy With Chemotherapy, Biosimilars Of Trastuzumab
3) By Other Types: Chemotherapy Agents, Targeted Therapy Agents, Immunotherapy Agents, Supportive Care Medications
Gastric Cancer Drugs Market Trends: What’s Defining The Industry’s Next Phase?
Companies active in the gastric cancer drugs market are dedicated to developing innovative products, such as CLDN18.2-targeted treatments, aiming to enhance the efficacy of therapies and provide more personalized patient options. CLDN18.2-targeted treatment refers to therapies specifically designed to target claudin 18.2 (CLDN18.2), a protein predominantly expressed in certain epithelial tissues, including the gastric epithelium. For instance, in October 2024, Astellas Pharma Inc., a Japan-based company, obtained approval from the Food and Drug Administration (FDA), a US-based federal agency for protecting public health, for VYLOY (zolbetuximab). VYLOY (zolbetuximab) is the first and only CLDN18.2-targeted treatment utilized for advanced gastric and gastroesophageal junction cancer where tumors are CLDN18.2 positive. The treatment is administered in combination with fluoropyrimidine- and platinum-based chemotherapy regimens, and it is indicated for adults with locally advanced unresectable negative gastric or gastroesophageal junction cancer adenocarcinoma.
Gastric Cancer Drugs Market Top Companies Driving Competitive Growth
Major companies operating in the gastric cancer drugs market are F. Hoffmann-La Roche, Eli Lilly and Company, Jiangsu HengRui Medicine, Biocon, Sanofi, PV Pharma Healthcare (India), Novartis Oncology, Arlak Biotech (India), CStone Pharma (China), CARsgen Therapeutics (China), JW Therapeutics (China), BeiGene (China), Takeda Pharmaceuticals (Japan), Astellas Pharma Inc. (Japan), Daiichi Sankyo, AstraZeneca plc, GlaxoSmithKline plc, Biocad, Bristol-Myers Squibb, Celon Pharma, Celltrion Inc., Merck & Co. Inc., Pfizer Inc., Sandoz AG (Novartis), Eurofarma Laboratórios S.A., TUTEUR Argentina / Pierre Fabre Group, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Mylan Laboratories, Gilead Sciences, BMS
View The Full Gastric Cancer Drugs Market Report:
Gastric Cancer Drugs Market Regional Breakdown: Where Is Demand Concentrated?
North America was the largest region in the gastric cancer drugs market in 2025. Middle East is expected to be the largest growing region in the global gastric cancer drugs market share during the forecast period. The regions covered in the gastric cancer drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model